Maintenance therapy for chronic lymphocytic leukaemia

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Maintenance therapy for B-chronic lymphocytic leukemia.

Although modern treatment options for B-chronic lymphocytic leukemia (CLL) produce high response rates, virtually all patients relapse, presumably due to the persistence of minimal residual disease (MRD). Novel approaches that maintain response and therefore delay growth of MRD may ultimately improve survival outcomes. In CLL, any type of continued therapy must be not only well tolerated but al...

متن کامل

Chronic lymphocytic leukaemia.

Chronic lymphocytic leukaemia is the commonest of the leukaemias and occurs most often in the elderly. The identification of presenting features that correlate adversely or favourably with survival has allowed the rational development of new treatment strategies.

متن کامل

Chronic lymphocytic leukaemia (CLL)

Typically, proliferation of mature small lymphocytes of normal morphology; lymphocytes with more abundant cytoplasm may be present. When prolymphocytes are 10% or greater they are classified as 'chronic lymphocytic leukaemia-prolymphocytic leukaemia'. The main immunophenotypic features that define BCLL are: the predominant population shares B-cell markers CD19, CD20, and CD23 with the CD5 antig...

متن کامل

Stem cell transplantation for chronic lymphocytic leukaemia.

Early results of autologous stem cell transplantation (ASCT) in chronic lymphocytic leukaemia (CLL) suggested a significant proportion of patients remained disease-free for years, raising the possibility of cure. More recent studies have shown no evidence of a plateau in the survival curves indicating that, at best, ASCT may only prolong disease-free survival. Problems remain over progenitor ce...

متن کامل

Murine models for chronic lymphocytic leukaemia.

CLL (chronic lymphocytic leukaemia) is characterized by the clonal outgrowth of B-lymphocytes with the distinctive phenotype: CD19(hi)CD5(+)CD23(+)IgM(lo). These malignant B-cells accumulate in the PB (peripheral blood) and lymphoid organs, and are generally arrested at the G(0)/G(1)-phase of cell cycle and display a resistance to apoptosis. To date, most of the CLL research has been carried ou...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Cochrane Database of Systematic Reviews

سال: 2019

ISSN: 1465-1858

DOI: 10.1002/14651858.cd013474